Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9885016 | 0.84 | PDE10A (0.47) | KMT2AKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL12677961 | 0.82 | CRHBP (0.49) | KMT2AKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL2401439 | 0.81 | HTR3A (0.58) | KDM4EALDH1A1CYP1A2HTR3AHTR3E | |
| SCHEMBL9885000 | 0.79 | KMT2A (0.53) | KMT2AKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL1026934 | 0.79 | HTR2C (0.64) | KMT2AKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL1713569 | 0.77 | ALDH1A1 (0.66) | KMT2AKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL15344982 | 0.77 | HRH3 (0.46) | KMT2AKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL15854633 | 0.77 | CYP11B1 (0.39) | KMT2AKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL12988893 | 0.75 | CHRM4 (0.41) | KMT2AKDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL2007079 | 0.74 | KDM4E (0.57) | KMT2AKDM4EMEN1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | claimed |
| US-20090227614-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | claimed |
| EP-1987034-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmceuticals Incorporated (US) | 2008-11-05 | — | — | EP | claimed |
| WO-2007100670-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-07 | — | — | WO | claimed |
| US-8263605-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| EP-1987034-B1 | SPIRO CONDENSED PIPERIDINES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20090227614-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| EP-1987034-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmceuticals Incorporated (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007100670-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227614-A1 | Modulators of Muscarinic Receptors | CHRM5, CHRM3, CHRM2 | KMT2A 2268/4885KDM4E 2459/4885MEN1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.